Skip to content
Peptigraph home
Shop Peptides50% off*

How to Inject Survodutide: Sites, Syringes and Steps

Where to inject Survodutide, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Survodutide in studies: not reported in study abstracts (PubMed search, 2 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

How the trials gave survodutide

The first phase 3 trial gave survodutide as a once-weekly subcutaneous injection, adjusted up to 3.6 mg or 6.0 mg.[7]

The phase 3 trial in people with diabetes gave once-weekly subcutaneous survodutide at 3.6 mg or 6.0 mg or placebo.[8]

The phase 2 MASH trial used a 24-week rapid-dose-escalation phase, then a 24-week maintenance phase.[9]

The cirrhosis trial moved from one 0.3 mg subcutaneous dose to weekly doses escalated from 0.3 mg to 6.0 mg over 24 weeks, then 4 weeks of maintenance.[10]

One phase 2 diabetes arm pair was dosed twice weekly (1.2 or 1.8 mg), alongside once-weekly arms up to 2.7 mg.[11]

What the registry says about the device

The registry record for the diabetes phase 3 trial describes the intervention as a once-weekly subcutaneous injection from a pre-filled syringe.[12]

The registry record for the first phase 3 trial lists a once-weekly subcutaneous injection without naming a device.[13]

No approved administration steps

Drugs@FDA returned no matches for survodutide, so no approved label with injection-site, rotation or device steps exists to quote.[14]

Common questions

Where do you inject Survodutide?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for Survodutide?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is Survodutide injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

How is survodutide injected in the studies?

The phase 3 trials gave it as a once-weekly subcutaneous injection.[7]

More on Survodutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.Legal statusFDA, compounding and WADA status with dates.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: survodutide[tiab] OR BI456906[tiab] (86 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (56 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
  8. 8Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
  9. 9A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
  10. 10Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Journal of hepatology · 2024PMID 38857788Accessed 2 Oct 2026
  11. 11Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026
  12. 12A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  13. 13A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "survodutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.